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Abstract 
Depressive Symptoms in the Cognitive-Behavioural Treatment of Generalized Anxiety 
Disorder 
Elizabeth A. Hebert 
Generalized anxiety disorder (GAD) is characterized by anxiety, excessive and 
uncontrollable worry, and somatic symptoms such as muscle tension and difficulty 
concentrating (DSM-IV-TR, American Psychiatric Association, 2000). GAD is linked to 
symptoms of depression both theoretically and empirically, but there is currently no 
consensus as to how co-occurring depressive symptoms affect GAD treatment outcome. 
Dugas and colleagues have developed an efficacious cognitive-behavioural treatment 
(CBT) based on a model of GAD that centres upon intolerance of uncertainty. This CBT 
program has demonstrated consistent reductions in GAD symptom severity by 
posttreatment (e.g., Dugas et al., 2010); however, not all individuals achieve full 
remission of GAD for reasons that are currently unclear. The first goal of this study was 
to determine the relationship between depressive symptoms and short- and long-term 
GAD treatment outcome. The second goal was to determine the relationship between 
depressive symptoms and GAD treatment engagement. The results indicated that 
depressive symptoms at pretreatment were largely unrelated to posttreatment severity of 
GAD, worry, and somatic anxiety or to treatment engagement. Posttreatment depressive 
symptoms were not related to the severity of overall GAD symptoms, worry, and somatic 
anxiety at 18-month follow-up. The theoretical and clinical implications of these findings 
are discussed. 
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Depressive Symptoms in the Cognitive-Behavioural Treatment of Generalized Anxiety 
Disorder 
 Numerous protocols have been developed for the treatment of generalized anxiety 
disorder (GAD; e.g., Borkovec & Costello, 1993; Dugas & Ladouceur, 2000; Wells & 
King, 2006), with most demonstrating good efficacy. However, some individuals do not 
achieve full remission of their disorder following treatment, for reasons that have not 
been conclusively established. One potential explanation is the presence of depressive 
symptoms, which often co-occur with GAD. Symptoms of depression are not directly 
targeted during treatments for GAD and may interfere with effective treatment 
implementation. The current study aims to clarify the impact of depressive symptoms on 
short- and long-term treatment outcome as well as treatment engagement in a cognitive-
behavioural treatment for GAD. 
 GAD is one of the most common anxiety disorders and one that can have a 
profound effect on the lives of its sufferers in professional, personal, and social spheres 
(Wittchen, 2002). According to the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision (DSM-IV-TR; American Psychiatric 
Association, 2000), the main diagnostic feature of GAD is excessive anxiety and worry 
that occurs more days than not for at least six months and that is centred around a number 
of events or activities. This anxiety and worry causes significant distress or impairment in 
essential areas of functioning and is difficult to control. Additionally, in order to meet 
diagnostic criteria for GAD, an individual must experience three or more of the following 
somatic symptoms: restlessness, difficulty concentrating, irritability, fatigue, muscle 
tension, and sleep disturbance. 
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 Approximately 5.1% of the population will meet GAD diagnostic criteria in their 
lifetime (Wittchen, Zhao, Kessler, & Eaton, 1994), with one-month prevalence rates as 
high as 7.9% in primary-care settings (Maier et al., 2000). In addition to its high 
prevalence, GAD results in significant impairments in numerous domains of functioning. 
GAD is associated with impairments in close relationships and social life (Massion, 
Warshaw, & Keller, 1993; Stein & Heimberg, 2004), career functioning (Greenberg et 
al., 1999; Wittchen, Carter, Pfister, Montgomery, & Kessler, 2000; Wittchen et al., 1994), 
and physical health (Hoffman, Dukes, & Wittchen, 2008; Wittchen et al., 2002). GAD is 
also associated with significant costs to the health care system, including increased visits 
to general practitioners and medical specialists such as cardiologists and gynaecologists 
(Greenberg et al., 1999). Considering the disorder’s high prevalence rates, significant 
associated impairments, and economic burden, effective treatment for GAD is essential. 
Dugas and Ladouceur (2000) have developed a cognitive-behavioural treatment 
(CBT) protocol based on a model of GAD that is centred upon intolerance of uncertainty 
(Dugas, Gagnon, Ladouceur, & Freeston, 1998). Intolerance of uncertainty is a 
dispositional characteristic that develops from a set of negative beliefs regarding 
uncertainty and its implications (Dugas & Robichaud, 2007). This CBT protocol has 
demonstrated efficacy in decreasing symptoms of GAD in numerous well-controlled 
studies (e.g., Dugas et al., 2003; Ladouceur, 2000). However, not all individuals treated 
for GAD achieve full remission of their disorder, the reasons for which remain unclear. 
As previously mentioned, one potential barrier to effective treatment for individuals with 
GAD may be symptoms of depression. 
Defining Depression 
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 What is commonly referred to as “depression” is increasingly recognized as a 
dimensional construct (Lewinsohn, Soloman, Seeley, & Zeiss, 2000) with a range of 
clinical presentations according to the number, duration, and severity of symptoms. 
Depressive disorders include both those traditionally recognized as “threshold” or 
“clinical” conditions (major depressive disorder and dysthymic disorder) as well as 
“subthreshold” or “subclinical” disorders (minor depressive disorder, recurrent brief 
depressive disorder, and subsyndromal symptomatic depression). These conditions differ 
in terms of the number, type, severity, and duration of depressive symptoms but are all 
associated with clinically significant distress and impairment. Common symptoms 
include low mood, anhedonia, appetite disturbance, fatigue, sleep disturbance, 
psychomotor retardation or agitation, and suicidal ideation. 
Depression can be assessed in a number of ways, including: (1) diagnosis based 
on set criteria or (2) elevated depression scores on self-report measures. According to the 
DSM-IV-TR, a diagnosis of major depressive disorder (MDD) requires low mood or 
anhedonia and at least five additional symptoms of depression for at least two weeks. 
Dysthymic disorder (dysthymia) a requires low mood for at least two years with at least 
two additional symptoms. Minor depression has the same criteria as MDD, but with only 
two to four depressive symptoms (one of which must be low mood or anhedonia). 
Recurrent brief depression has the same criteria as MDD, but with symptom duration of 
less than two weeks (American Psychiatric Association, 2000). Subsyndromal 
symptomatic depression requires at least two symptoms of depression for at least two 
weeks, but with no low mood or anhedonia. Emerging research demonstrates that 
clinically significant distress and impairment can be present even when low mood or 
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anhedonia is absent, as is the case in subsyndromal symptomatic depression (Sadek & 
Bona, 2000). 
Depression can also be measured by self-report questionnaires such as the Beck 
Depression Inventory, 2nd Edition and the Center for Epidemiologic Studies Depression 
Scale (Gotlib, Lewinsohn, & Seeley, 1995; Sadek & Bona, 2000). Clinically significant 
impairment and distress have been found in individuals with elevated scores on such self-
report measures of depression even when criteria are not met for a threshold depressive 
disorder such as major depressive disorder (MDD) or dysthymia (Gotlib et al., 1995). 
There is therefore substantial evidence for conceptualizing depression as a dimensional 
syndrome, with clinically significant impairment and distress not limited to the highest 
end of the spectrum. 
Depression and GAD 
GAD and depression are strongly linked both empirically and theoretically. 
Empirical evidence is mainly derived from investigations of comorbidity, structural 
analyses, and phenotypic and genotypic similarities. The majority of this research has 
been conducted using MDD and dysthymia criteria as the definition of “depression”. 
There is a high rate of comorbidity between GAD and MDD/dysthymia even as 
compared to other comorbid conditions (Kendler, Gardner, Gatz, & Pederson, 2007; 
Sanderson, Di Nardo, Rapee, & Barlow, 1990). For instance, in a community-based 
epidemiological study, Kessler and colleagues (2005) found that the bivariate correlation 
between 12-month GAD and MDD was 62% – higher than the correlations between 
GAD and any other measured DSM-IV disorder. Further, both confirmatory and 
exploratory factor analyses suggest that GAD has more robust associations with MDD 
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and dysthymia than with other anxiety disorders (Brown, Chorpita, & Barlow,1998; 
Krueger, 1999; Vollebergh et al., 2001). GAD and MDD also have phenotypic and 
genotypic similarities. Somatic anxiety symptoms and depressive symptoms overlap 
significantly. In fact, the only somatic anxiety symptoms characteristic of GAD that do 
not overlap with DSM-IV criteria for MDD are irritability and muscle tension. Muscle 
tension appears to be the only somatic symptom uniquely related to worry, suggesting 
that the other somatic anxiety symptoms show little specificity to GAD (Joorman & 
Stöber, 1999). This symptom overlap may at least partially account for the disorders’ 
high comorbidity and structural relationships (Menin, Heimberg, Fresco, & Ritter, 2008). 
Finally, GAD and MDD share genetic vulnerabilities that suggest pleiotropy (Gorwood, 
2004). 
Due to these similarities, GAD’s status as an independent disorder has been 
questioned. However, GAD and unipolar depressive disorders can be reliably 
distinguished in terms of risk factors, clinical presentation, cognitive content, and 
cognitive biases. Again, most of this differentiation has been examined in terms of GAD 
and MDD. Environmental risk factors differ between GAD and MDD (Moffitt et al., 
2007; Kendler et al, 2007; Kendler, Hettema, Butera, Gardner, & Prescott, 2003; Kessler, 
2008). GAD and MDD also differ in terms of illness course (Fergusson, Horwood, & 
Boden, 2006), as well as some aspects of symptomatology. 
Additionally, specificity has been demonstrated in terms of both cognitive content 
and biases. For example, both anxiety and depression are associated with interpretive 
biases regarding the probability of the occurrence of negative events (e.g., Butler & 
Matthews, 1983). However, Clark and colleagues (1990) found that threat-related 
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cognitions relating to anticipated harm and danger were more prominent in anxious 
individuals, whereas negative cognitions related to failure, loss, low self-worth, and 
hopelessness were more prominent in depressed individuals. More specifically, 
individuals with GAD demonstrate attentional biases to threatening stimuli, a 
phenomenon not found in individuals with MDD (Mineka, Rafaeli, & Yovel, 2003). 
There is also evidence of differentiation between GAD and depression in terms of 
approach to certainty. Intolerance of uncertainty is associated with both GAD (Dugas, 
Buhr, & Ladouceur, 2004) and MDD (Gentes & Ruscio, 2011). Repetitive, negative 
cognitions may explain this relationship. Worry partially mediates the relationship 
between intolerance of uncertainty and anxiety, whereas rumination fully mediates the 
relationship between intolerance of uncertainty and depression (Yook, Kim, Suh, & Lee, 
2010). When intolerant of uncertainty, worrying increases anxiety whereas ruminating 
increases depression. This may relate to hopelessness, a key distinguishing feature 
between anxiety and depression (Alloy, 1991; Alloy, Kelly, Mineka, & Clements, 1990). 
Individuals with MDD may react to uncertainty with hopelessness, converting an 
uncertain stimulus into a certain, negative one (Gentes & Ruscio, 2011). This coincides 
with research showing greater certainty in the occurrence of future negative events in 
individuals with MDD (Miranda & Mennin, 2007). Furthermore, certainty in an absence 
of future positive events is associated with depression but not GAD, with hopelessness 
mediating this relationship (Miranda, Fontes, & Marroquín, 2008). Thus, GAD and MDD 
share similarities in cognitive content and biases but can be successfully differentiated. 
 Theoretical models have been used to account for these similarities and 
differences between GAD and depressive disorders. Perhaps most widely known is the 
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tripartite model, which states that anxiety and depressive disorders share a common 
factor of negative affect. These broad disorder types are distinguished by positive affect 
and physiological hyper-arousal: according to the tripartite model, depressive disorders 
demonstrate comparatively low positive affect whereas anxiety disorders demonstrate 
comparatively high physiological arousal. This has been examined empirically in 
structural analyses of GAD and MDD with generally good support. GAD and MDD 
consistently share a strong association with a higher-order factor of negative affect when 
examining diagnostic data (Brown et al., 1998; Krueger, 1999; Vollebergh et al., 2001) as 
well as self-report symptom data (Brown et al., 1998). MDD demonstrates a relationship 
with low positive affect when examining both symptom clusters and diagnostic data 
(Brown et al., 1998, Watson et al., 1995). Finally, a recent conceptualization suggests that 
worry increases the baseline level of both negative affect and physiological arousal, while 
suppressing further increases in arousal when exposed to fear-evoking stimuli (Newman 
& Llera, 2011). This is consistent with the tripartite model as well as findings that anxiety 
symptoms in general are associated with higher levels of physiological arousal (Watson 
et al., 1995). It also clarifies earlier findings showing a relationship between GAD and 
suppression of autonomic reactivity (Borkovec, Alcaine, & Behar, 2004; Brown et al., 
1998; Thayer, Friedman, & Borkovec, 1996). 
 Other theoretical models have been proposed to further elucidate the similarities 
and differences between unipolar depressive and anxiety disorders – and between GAD 
and MDD more specifically. An integrative hierarchical model (Mineka, Watson, & 
Clark, 1998) was put forth as an extension and amalgamation of the tripartite model and 
Barlow’s hierarchical organization of anxiety disorders (Barlow, 1991; Zinbarg & 
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Barlow, 1996). This integrative hierarchical model posits that each disorder has both a 
common and a unique component – that is, a component it shares with other disorders 
and a component that is uniquely its own. For example, depression and GAD share the 
common component of negative affectivity. Depression’s theorised specific components 
are disinterest and anhedonia (Mineka et al., 1998), as an absence of positive affect is 
also present in social anxiety disorder (Brown et al., 1998). This does not account for 
possible depression subtypes that present without anhedonia, such as subsyndromal 
symptomatic depression or depression presentations in certain ethnic groups. In terms of 
GAD’s unique components, two elements that appear relatively specific to GAD are 
muscle tension and generalized worry. In sum, GAD and depressive disorders share 
substantial similarities but can be successfully differentiated both empirically and 
theoretically. 
 As previously stated, the co-occurrence of GAD and depression is common. It 
also comes with substantial impairment and distress. As compared to “pure” GAD, GAD 
with comorbid depression is marked by more severe GAD symptoms and increased 
impairments. Using data from the National Comorbidy Study and the Midlife 
Development in the United States Survey, Kessler and colleagues (1999) found that 
individuals with comorbid GAD and MDD show lower quality of life in terms of social 
functioning, physical health, and vitality. Unsurprisingly, individuals with comorbid 
GAD and MDD also had greater impairment in mental health than individuals with 
“pure” GAD or “pure” MDD. Risk of suicide is heightened in those with comorbid GAD 
and MDD as compared to pure GAD (Masi, Mucci, Favilla, & Millepiedi, 2001; 
Wittchen et al., 2002). Individuals with comorbid MDD and GAD also have earlier ages 
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of onset than those with “pure” GAD or “pure” MDD (Moffitt et al., 2007). Finally, 
although individuals with GAD already utilize a disproportionate level of health services 
(Greenberg et al., 1999), comorbidity appears to increase treatment seeking (Wittchen et 
al., 1994). In sum, comorbid depression increases the distress and impairment associated 
with GAD. For this reason, examining the impact of co-occurring depressive symptoms 
on GAD treatment outcome is essential. 
Examining the Role of Depressive Symptoms in GAD Treatment 
 Despite the increased impairment associated with GAD and comorbid depression, 
there is a lack of consensus as to how symptoms of depression affect GAD treatment 
efficacy. In fact, there is a dearth of research examining the effects of total or specific 
comorbidities on GAD treatment; for example, in a large meta-analysis examining the 
effects of comorbidity on anxiety treatment outcomes only one of the included studies 
examined GAD treatment specifically (Olatunji, Cisler, & Tolin, 2010). In the extant 
literature, findings regarding the impact of depression on GAD treatment outcome are 
mixed. 
In the available literature, several studies show that comorbid depression has a 
detrimental effect on short-term GAD treatment outcome. For example, van Balkom and 
colleagues (2008) found that comorbid depression (MDD and/or dysthymia) predicted 
lowered responsiveness to CBT for GAD. Similarly, Crits-Christoph and colleagues 
(2004) found that comorbid MDD was associated with poorer short-term treatment 
outcome in a supportive-expressive psychodynamic therapy for GAD (Crits-Christoph et 
al., 2004). Comorbid MDD has also been associated with decreased likelihood of 
spontaneous GAD remission and greater GAD chronicity when untreated (Bruce, 
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Machan, Dyck, & Keller, 2001; Bruce et al., 2005). The reverse has also been 
demonstrated: individuals with MDD and comorbid GAD show higher rates of attrition 
and increased latency of therapeutic medication effects (Brown, Schulberg, Madonia, 
Shear, & Houck, 1996). These findings are supplemented by numerous studies suggesting 
that comorbid depressive symptoms are associated with poorer short- and long-term 
treatment outcomes in other anxiety disorders (e.g., Emmanuel, Simmonds, & Tyrer, 
1998; Lydiard & Brawman-Mintzer, 1998), including social phobia (Chambless, Tran, & 
Glass, 1997; Ledley et al., 2005; Marom, Gilboa-Schechtman, Aderka, Weizman, & 
Hermesh, 2009) and panic disorder (Lecrubier, 1998), suggesting these results may also 
be found in GAD treatment outcome.  
However, several recent studies suggest that comorbid depressive disorders may 
not negatively impact treatment for GAD (Davis, Barlow, & Smith, 2010). In fact, in two 
recent investigations elevated depression scores at pre-treatment predicted improved 
short- and long-term CBT outcomes in adults (Newman, Przeworksi, Fisher, & 
Borkovec, 2010) and older adults (Wetherell et al., 2005) with GAD. Thus, given 
equivocal findings in the extant literature, our study aims to further elucidate the 
relationship between comorbid depression and GAD treatment outcome. 
 If elevated depression negatively impacts GAD treatment, it may do so in a 
number of ways. First, there is a robust relationship between treatment expectancy and 
CBT outcome for GAD (Barlow, Rapee, & Brown, 1992; Borkovec & Costello, 1993; 
Borkovec & Mathews, 1988; Newman & Fisher, 2010), which has been replicated in 
other forms of psychotherapeutic interventions for GAD (Crits-Christoph et al., 2004). 
Change in treatment expectancy has also been shown to partially mediate the relationship 
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between pretreatment and posttreatment severity of GAD (Newman & Fisher, 2010). 
Although this has not been studied directly, the presence of depressive symptoms may 
interfere with expectancies in the treatment of GAD, thus reducing symptom change by 
posttreatment. A significant symptom associated with depression is hopelessness, which 
mediates the relationship between depressive symptoms and reduced expectancy of 
positive future outcome (Miranda et al., 2008). Hopelessness and certainty in a lack of 
positive future events may extend to expectancies regarding treatment outcome. That is, 
individuals with depressive symptoms may have less positive treatment outcome 
expectancies. Given the robust relationship between treatment expectancy and outcome, 
this may be particularly problematic. 
Second, although both depression and GAD are associated with negative problem 
orientation, depression has been linked with specific deficits in rational problem-solving 
style. Depressed individuals with high trait rumination generate poorer problem solutions 
than depressed individuals with low trait rumination and non-depressed individuals 
(Donaldson & Lam, 2004). Several studies have demonstrated that depression is 
associated with an avoidant problem-solving style, in which individuals seek to avoid 
thinking about or attempting to solve their problems (Becker-Weidman, Jacobs, 
Reinecke, Silva, & March, 2010; Reinecke, DuBois, & Schultz, 2001). This avoidant 
problem solving style predicts less improvement in depression severity over the course of 
treatment and greater suicidality (Becker-Weidman et al., 2010). Furthermore, this style 
of problem-solving could be particularly problematic in an active therapy context such as 
CBT: it may interfere with the individual’s approach to treatment in general or the 
cognitive and behavioural exercises in particular. More specifically, in our CBT 
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treatment protocol for GAD an avoidant problem-solving style could be problematic in 
terms of between-session and in-session exercises such as monitoring of worry; accessing 
automatic thoughts, interpretations, and beliefs regarding uncertainty and willingness to 
challenge them; effective creation of anxiety-provoking imaginal exposure scenarios; and 
effective problem-solving training. 
Third, clinical observation suggests that depressive symptoms may interfere with 
imaginal exposure, an important component of the present study’s treatment for GAD 
(Dugas & Robichaud, 2007). Clients with comorbid depression may include 
depressogenic elements into their imaginal exposure scenarios, thus increasing feelings 
associated with depression while inhibiting the elicitation of anxiety. 
Fourth, the presence of depressive symptoms may decrease treatment motivation. 
For example, common symptoms of unipolar depression include a loss of interest in 
activities, fatigue, and behavioural inactivity. Such depressive symptoms may be 
particularly problematic in the context of CBT, which is an active treatment modality. 
Typical CBT protocols involve collaboration between the clinician and client as well as 
active involvement of the client in- and between- sessions in terms of both cognitive and 
behavioural exercises. Furthermore, the cognitive and behavioural exercises used in CBT 
paradigms can create short-term discomfort and distress in clients as they challenge and 
reassess their beliefs, interpretations, and behaviours; these exercises also require 
significant effort both in and outside of therapy sessions (Beck, 1995). In our CBT 
program designed to target GAD, clients are asked to engage in a number of potentially 
distressing exercises requiring substantial effort such as monitoring worry and imaginal 
exposure. Completing such effortful and anxiety-provoking exercises requires 
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considerable motivation, which may be lower in individuals with depressive symptoms. 
For these reasons, the presence of depressive symptoms may interfere with the effective 
implementation of CBT protocols in general and our CBT program for GAD in 
particular.  
 In sum, we must consider (1) research demonstrating the potentially problematic 
nature of depression in the treatment of GAD and anxiety disorders in general, (2) 
clinical observations regarding the treatment-interfering nature of depression, and (3) the 
potential mechanisms of interference proposed. Given these factors, this study posits the 
more conservative hypothesis that depressive symptoms will be associated with poorer 
treatment outcome on a number of short- and long-term indices. 
Addressing Limitations of Previous Research 
 This study aims to address a number of limitations prevalent in the extant 
literature. Considering the broader treatment outcome literature, examining the potential 
impact of depressive symptoms on short- and long-term treatment outcomes is a valuable 
and necessary exercise. Despite the possibility that depressive symptoms interfere with 
treatment outcome in GAD, studies often exclude participants with comorbid depression 
(e.g., Borkovec, Abel, & Newman, 1995; Borkovec & Costello, 1993; Butler & 
Anastasiades, 1988; Durham, Allan, & Hackett, 1997) even when specifically examining 
the effects of Axis I comorbidity on GAD treatment outcome. Given the high rate of 
comorbidity between GAD and depressive disorders, the exclusion of participants with 
comorbid depression creates unrepresentative samples and results from such studies will 
lack complete information and generalizability. 
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  A limitation present in previous research examining the role of comorbid 
depression in the treatment of GAD relates to the categorical assessment of depression 
(e.g., Provencher, Ladouceur, & Dugas, 2006). These studies have assessed depression 
dichotomously, meaning that depression is either present or absent. Typically, this is 
assessed as the presence or absence of MDD and dysthymia. This approach to assessing 
depression has several important disadvantages. One is that there may be few participants 
who meet the clinical threshold for depression, creating severely unbalanced groups and 
low power for statistical tests. Another disadvantage is that the presence of subthreshold 
depressive symptoms may have an impact on treatment outcome, even though these 
symptoms do not meet the clinical threshold for a depressive disorder, such as MDD. For 
example, patients with an anxiety disorder who also have subthreshold depressive 
symptoms display delayed latency for the onset of therapeutic effects, lower overall 
recovery rates, and higher relapse rates (Brown et al., 1996; Lecrubier, 1998; Maier, 
Gansicke, & Weiffenbach, 1997). In this sense, information with potential clinical 
importance may be lost. To address these issues, the present study assessed depression 
continuously. In other words, depression was viewed as a syndrome ranging in severity. 
 Another limitation in the available literature relates to the lack of long-term 
outcome assessment following treatment termination. To our knowledge, only one study 
examining GAD treatment has had a follow-up point beyond one year (Newman et al., 
2010). Thus, the current study will examine long-term GAD treatment outcome at 18-
months posttreatment in order to provide a more realistic, conservative, and clinically 
useful estimate of the long-term maintenance of treatment gains. 
Goals and Hypotheses 
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 This study examined the role of depressive symptoms in treatment outcome for a 
CBT protocol for GAD. The two main goals of this study were to determine if: (1) higher 
levels of depressive symptoms at pre- and posttreatment predict poorer short- and long-
term treatment outcomes; and (2) higher pretreatment levels of depressive symptoms 
predict treatment non-engagement. Specifically, the study had four main hypotheses: (1) 
greater severity of depressive symptoms at pretreatment would predict greater severity of 
GAD symptoms at posttreatment; (2) greater severity of depressive symptoms at 
posttreatment would predict greater severity of GAD symptoms at 18-month follow-up; 
(3) greater severity of depressive symptoms at pretreatment would predict greater 
likelihood of drop-out during treatment; and (4) greater severity of depressive symptoms 
at pretreatment would predict fewer treatment sessions completed. 
Method 
Participants 
 The final sample consisted of 91 Francophone adults (females = 72) between the 
ages of 18 and 64 with a primary diagnosis of GAD. The sample was on average middle-
aged (M = 43.28 years, SD = 12.07) with the following ethno-racial composition: 90.1% 
White (n = 82), 4.4% Native American (n = 4), 1.1% African-American (n = 1), and 
2.2% “other” (n = 2). The majority of participants were married (42.9%, n = 39) or in 
conjugal relationships (33.0%, n = 30). The sample was also highly educated, with 63.8% 
of participants having completed a Bachelor’s degree or higher. The majority of 
participants currently maintained full-time (51.6%, n = 47) or part-time (17.6%, n = 16) 
employment, with this being the primary source of income for most participants (72.5%, 
n = 66). At intake, the sample had had GAD for an average of 9.92 years (SD = 10.33). In 
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addition, the sample had an average GAD severity rating of 5.84 (SD = 0.73) on the 
Clinician’s Severity Rating scale of the Anxiety Disorders Interview Schedule for DSM-
IV, an average worry score of 63.02 (SD = 7.31) on the Penn State Worry Questionnaire, 
and an average somatic anxiety score of 21.09 (SD = 3.58) on the Somatic subscale of the 
Worry and Anxiety Questionnaire. The sample also had an average of 0.98 (SD = 0.82) 
non-depressive comorbid conditions at pretreatment. Finally, the sample’s average 
pretreatment depression score was 16.78 (SD = 9.57) on the Beck Depression Inventory, 
2nd Edition, which corresponds to “mild” depression (see Measures for all instrument 
properties). 
Procedure 
 Participants were recruited from the Anxiety Disorders Clinic of the Hôpital du 
Sacré-Cœur de Montréal or from bi-annual advertisements placed in a local newspaper. 
Prior to enrolment in the treatment program, two independent assessors interviewed each 
potential participant using different structured diagnostic interviews in order to assess the 
reliability of the initial diagnoses. A team psychiatrist conducted the initial assessment 
using the Mini International Neuropsychiatric Interview Version 5.0 (Sheehan et al., 
1994), rating the severity of each diagnosed condition on a scale of 0-8 using the 
Clinician’s Severity Rating scale (Di Nardo, Brown, & Barlow, 1994). If the participant 
met criteria for primary diagnosis of GAD (i.e., GAD severity was 4 or greater and was at 
least 1 point higher than other diagnosed conditions), a team psychologist then conducted 
a second diagnostic assessment using the Anxiety Disorders Interview Schedule for DSM-
IV (Di Nardo, Brown, & Barlow, 1994). The severity of each diagnosed condition was 
again rated using the Clinician’s Severity Rating scale. Following these assessments, a 
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final severity rating for each disorder was determined by consensus during a team 
meeting with the Principal Investigator, M. J. Dugas. Participants who received a primary 
diagnosis of GAD and who met the following additional inclusion criteria were accepted 
into the study: (1) no change in medication dose or type in 4 to 12 weeks before study 
entry (4 weeks for benzodiazepines, 12 weeks for antidepressants and hypnotics); (2) 
willingness to keep medication status stable while participating in the study (i.e., no 
changes in type of medication and no increase in dosage); (3) no use of herbal products 
known to have central nervous system effects 2 weeks before study entry; (4) no evidence 
of suicidal intent, based on clinical judgment; (5) no evidence of current substance abuse, 
current or past schizophrenia, bipolar disorder, or organic mental disorder; (6) no current 
participation in other clinical trials; and (7) no evidence of anxiety symptoms due to a 
general medical condition, based on clinical judgment (e.g., hyperthyroidism, anaemia, 
hypoglycemia). Participants who met all inclusion criteria then completed another 
standardized interview, cognitive tasks and pretreatment questionnaires (see Measures) 
prior to beginning treatment. The standardized interview and cognitive tasks were not 
part of the current study and are not reported below. The order of the study questionnaires 
was quasi-counterbalanced across participants. 
The study used a within-subjects design, with measures administered at 8 
assessment points: pre- and posttreatment as well as 3-, 6-, 9-, 12-, 15-, and 18-month 
follow-ups. Treatment consisted of an empirically-supported CBT protocol for GAD, 
administered over 14 weekly sessions utilizing a treatment manual initially developed in 
earlier studies and revised for the current one (Dugas & Ladouceur, 2000; Dugas et al., 
2003; Ladouceur et al., 2000). The treatment components were: psychoeducation and 
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worry awareness training, reevaluation of the usefulness of worry, uncertainty 
recognition and behavioural exposure, problem-solving training, imaginal exposure, and 
relapse prevention. These components were designed to target specific processes in a 
cognitive model of GAD (Dugas & Robichaud, 2007), as well as simultaneously build 
tolerance and acceptance of uncertainty at each stage of treatment. As such, intolerance 
of uncertainty – the main component around which this cognitive model of GAD is based 
– was directly targeted throughout treatment. Four licensed psychologists experienced 
with CBT conducted treatment for all participants. 
Measures 
 Two structured diagnostic interviews were used prior to treatment to determine 
the presence and severity of GAD: the Mini International Neuropsychiatric Interview 
(MINI; Sheehan et al., 1998) and the Anxiety Disorders Interview Schedule for DSM-IV 
(ADIS-IV; Di Nardo, Brown, & Barlow, 1994). Three measures were used throughout 
treatment and follow-ups to measure GAD symptoms: overall GAD symptomatology was 
assessed using the Clinician’s Severity Rating scale of the ADIS-IV; worry was assessed 
using the Penn State Worry Questionnaire (PSWQ; Meyer, Miller, Metzger, & Borkovec, 
1990); and somatic anxiety was assessed using the somatic subscale of the Worry and 
Anxiety Questionnaire (WAQ; Dugas et al., 2001). Depressive symptoms such as self-
dislike, loss of interest, and worthlessness were assessed using the Beck Depression 
Inventory, 2nd Edition (BDI-II; Beck, Steer, & Brown, 1996). 
 The Mini International Neuropsychiatric Interview, Version 5.0 (MINI; Sheehan 
et al., 1998) is a semi-structured diagnostic interview that assesses 17 DSM-IV-TR Axis I 
disorders using 210 items. The MINI has demonstrated excellent inter-rater reliability for 
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GAD (κ = .98) and good test-retest reliability for GAD, measured over two days (κ = 
.78), using different interviewers for each assessment. The Clinician’s Severity Rating 
used with the ADIS-IV (see below) was used in conjunction with the MINI in the current 
study to provide a severity rating for each diagnosed disorder on a 9-point Likert scale. 
 The Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV; Di Nardo, 
Brown, & Barlow, 1994) is a semi-structured interview that assesses anxiety disorders 
and screens for several other Axis I disorders, including mood disorders. The Clinician’s 
Severity Rating provides severity ratings for each diagnosed disorder on a 9-point Likert 
scale, with scores ranging from 0 (“absent or none”) to 8 (“very severe”). A severity 
rating of 4 (moderate) represents the threshold of clinical significance. This means that 
scores of 4 or above indicate the presence of a clinically significant disorder, whereas 
scores below 4 indicate sub-clinical levels of a disorder. The ADIS-IV has good inter-
rater reliability for dimensional ratings of GAD (excessive worry, r = .73; uncontrollable 
worry, r = .78; clinical severity rating, r = .72) and for diagnostic reliability for GAD (κ 
=. 67; Brown, Di Nardo, Lehman, & Campbell, 2001). For the purposes of this study, the 
Clinician’s Severity Rating on the ADIS-IV (heretofore referred to as “ADIS-IV”) was 
used at pre- and posttreatment as well as across the six follow-ups to assess the severity 
of GAD. For the diagnostic assessment at posttreatment and across follow-ups, scores 
below 4.0 represented remission of GAD and scores of 4.0 or above represented non-
remission of GAD. 
 The Penn State Worry Questionnaire (PSWQ; Meyer, Miller, Metzger, & 
Borkovec, 1990) is a self-report questionnaire consisting of 16 items that measure the 
tendency to worry uncontrollably and excessively. Items are rated on a 5-point Likert 
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scale, with responses ranging from 1 ("not at all typical of me") to 5 ("very typical of 
me"). The French translation used in this study demonstrated good internal consistency (α 
= .81) in the current study and has shown excellent test-retest reliability over four weeks 
(r = .86; Gosselin, Dugas, Ladouceur, & Freeston, 2001). For the purposes of this study, 
the PSWQ was used at pre- and posttreatment as well as across follow-ups to assess the 
severity of worry continuously. 
 The Worry and Anxiety Questionnaire (WAQ; Dugas et al., 2001) is a self-report 
measure consisting of 11 items pertaining to GAD diagnostic criteria. The Somatic 
subscale of the WAQ (WAQ-Som) consists of six items assessing the somatic symptoms 
associated with GAD, which include restlessness, difficulty concentrating, irritability, 
muscle tension, sleep disturbance, and fatigue. The WAQ-Som was used in this study to 
complement the assessment of worry using the PSWQ. Each item is rated on a 5-point 
Likert scale, with responses ranging from 1 ("not at all") to 5 ("very severe"). The French 
version of the WAQ demonstrated adequate internal consistency (α = .74) in this study 
and has shown adequate test-retest reliability over 64 days (r = .75 for those who meet 
GAD diagnostic criteria; r = .83 for those who do not meet GAD diagnostic criteria; 
Dugas et al., 2001). For the purposes of this study, the WAQ-Som was used at pre- and 
posttreatment as well as across follow-ups to assess the severity of GAD somatic 
symptoms using a continuous approach. 
 The Beck Depression Inventory, 2nd Edition (BDI-II; Beck, Steer, & Brown, 
1996) is a self-report questionnaire assessing depressive symptoms such as 
worthlessness, loss of interest, and self-dislike. It consists of 21 groups of statements, 
each containing four statements that reflect differing degrees of depressive symptoms. 
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For each group, respondents indicate which statement best describes them over the 
preceding two weeks. Scores on each item range from 0 to 3. This measure demonstrated 
good internal consistency (α = .87) in the current study and shows evidence of content, 
factorial, and discriminant validity (Beck, Steer, & Brown, 1996). For the purposes of 
this study, the BDI-II was used at pre- and posttreatment to assess depressive symptoms 
continuously. 
Statistical Analyses 
 When testing all hypotheses, two variables were controlled for: the initial severity 
of the relevant GAD outcome measure (i.e., at pretreatment in the case of Hypotheses 1, 
3, and 4 and at posttreatment in the case of Hypothesis 2) and the total number of non-
depressive comorbid conditions (i.e., at pretreatment in the case of Hypotheses 1, 3, and 4 
and at posttreatment in the case of Hypothesis 2). The total number of non-depressive 
comorbid conditions was controlled for as overall comorbidity has been linked to poorer 
treatment outcomes and higher rates of relapse (e.g., Durham, Allan, & Hackett, 1997). 
Hypotheses 1 and 2 were examined using hierarchical linear regression due to its 
appropriateness in terms of our data set and research questions. Although Hierarchical 
Linear Modelling (Raudenbush, Bryk, & Congdon, 2006) was an analytic option, given 
the number of available assessment points, it was not pursued in the present investigation 
largely due to the nature of our treatment program. Conceptually, given the nature of the 
inclusion and exclusion criteria as well as the process of treatment itself, we expected 
there to be less variability in how participants change over time as compared to the 
variability between participants at a particular time point (in this case, at posttreatment 
and 18-month follow-up). Our research group has found this to be the case when 
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examining data from previous randomized control trials, and thus regressions were used 
in the current investigation. Hypothesis 3 was analyzed using hierarchical logistic 
regression, given its dichotomous outcome variable (i.e., drop-out status), whereas 
Hypothesis 4 was analyzed using hierarchical linear regression. 
Results 
Prior to the main analyses, statistical assumptions were assessed. All relevant 
variables were found to be normally distributed and free of multicollinearity. Linearity 
and homoscedasticity requirements were met for the relationships between pretreatment 
BDI-II scores and the GAD outcome measures (i.e., ADIS-IV, PSWQ, and WAQ-Som) 
at posttreatment. Linearity assumptions were met for the relationships between 
posttreatment BDI-II scores and the GAD outcome measures at 18-month follow-up. 
However, the assumption of homoscedasticity was violated between posttreatment BDI-II 
scores and the GAD outcome measures at 18-month follow-up. Heteroscedasticity may 
be more common in clinical data, for several theoretical reasons (Grissom, 2000). No 
action was taken to transform these variables as this can result in further statistical and 
interpretive problems. Therefore, the resulting regression analyses must be interpreted 
with some caution. 
Interrater Agreement on Diagnostic Status 
 We assessed interrater agreement on pretreatment GAD by comparing (1) primary 
diagnoses and (2) the severity of primary diagnoses on the MINI and ADIS-IV diagnostic 
interviews. Interrater agreement was met when the assessors agreed upon: (1) the primary 
diagnosis and (2) the severity of the primary diagnosis (i.e., a one-point difference or less 
between assessors on the Clinician’s Severity Rating of the primary diagnosis). Interrater 
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agreement was assessed in two ways. First, interrater agreement was assessed for the total 
sample of individuals assessed for inclusion in the treatment study (N = 147). The 
percentage agreement for this sample was 74.15%. Second, interrater agreement was 
assessed for the total sample of individuals included in the current study (N = 91), all of 
whom met diagnostic criteria for primary GAD at intake. The percentage agreement for 
this sample was 81.32%. 
Preliminary Analyses Regarding Treatment Outcome 
 Prior to testing our four main hypotheses, univariate t-tests were conducted to 
determine how GAD and depressive symptomatology changed as a result of GAD 
treatment and over the follow-up period. From pretreatment to posttreatment, scores on 
the BDI-II and all GAD measures (i.e., ADIS-IV, PSWQ, and WAQ-Som) decreased a 
statistically significant amount. The observed pattern of change from posttreatment to 18-
month follow-up on these measures was somewhat similar. There was a statistically 
significant decrease on ADIS-IV scores from posttreatment to 18-month follow-up, M = 
0.383, t (46) = 1.861, p = .034. There were also further decreases in PSWQ and WAQ-
Som scores over this time period, but they did not reach statistical significance. Finally, 
BDI-II scores increased slightly from posttreatment to 18-month follow-up, although this 
was also not statistically significant, M = -0.973, t (46) = -0.792, p = .217.  
Hypothesis 1 
 To test the hypothesis that greater severity of pretreatment depressive symptoms 
would predict greater severity of GAD symptoms at posttreatment, three hierarchical 
linear regressions were conducted using posttreatment ADIS-IV, PSWQ, and WAQ-Som 
as dependent variables while using pretreatment BDI-II scores as the main independent 
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variable. Only those participants who had completed all pre- and posttreatment measures 
(n = 78) were included in these analyses. All drop-outs (n = 13) were excluded. In each 
analysis, pretreatment severity of GAD symptoms on the relevant measure was controlled 
for in Step 1 and the number of non-depressive comorbid conditions at pretreatment was 
controlled for in Step 2. 
Results showed that pretreatment depressive symptom severity (BDI-II scores) 
predicted posttreatment GAD severity (ADIS-IV scores) at a statistically significant level 
(see Table 1). However, pretreatment depression severity did not significantly predict 
posttreatment worry severity (PSWQ scores; see Table 2) or somatic anxiety (WAQ-Som 
scores; see Table 3). Pretreatment depression severity accounted for 7% of the variance in 
posttreatment GAD severity over and above the control variables, F (3, 74) = 5.026, p = 
.003. Pretreatment depression severity had a positive relationship with posttreatment 
GAD severity: as the severity of pretreatment depressive symptoms increased, 
posttreatment GAD severity increased. This finding remained virtually unchanged when 
participants with MDD or dysthymia, as defined by scores of 4 or greater on the 
Clinician’s Severity Rating scale (n = 2), were excluded from the analysis. 
Hypothesis 2 
 To test the hypothesis that greater severity of posttreatment depressive symptoms 
would predict greater severity of GAD symptoms at 18-month follow-up, three 
hierarchical linear regressions were conducted using the ADIS-IV, PSWQ, and WAQ-
Som at 18-month follow-up as dependent variables while using posttreatment BDI-II 
scores as the main independent variable. Only those participants who had completed all 
follow-up assessment points (n = 47) were included in these analyses. All drop-outs (n = 
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13) as well as participants who had not fully completed the follow-up assessments (but 
who, nevertheless, had not dropped out of the study: n = 31) were not included. In each 
analysis, posttreatment severity of GAD symptoms on the relevant measure was 
controlled for in Step 1 and the number of non-depressive comorbid conditions at 
posttreatment was controlled for in Step 2.  
Results showed that posttreatment depression severity (BDI-II scores) did not 
statistically significantly predict 18-month follow-up scores on any of the GAD outcome 
measures (see Tables 4–6). To determine if the pretreatment level of depression would 
better predict GAD symptom severity at 18-month follow-up, hierarchical regression 
analyses were conducted using pretreatment BDI-II scores as the main independent 
variable and the same control variables. Similar findings were produced: pretreatment 
depression severity did not account for a statistically significant proportion of variance in 
any of the GAD outcome measures at 18-month follow-up. 
Hypothesis 3 
 To test the hypothesis that greater severity of pretreatment depressive symptoms 
would predict drop-out status (drop-out versus treatment completer), a logistic regression 
analysis was conducted using the full sample (N = 91). Pretreatment ADIS-IV scores 
were controlled for in Step 1 and the number of non-depressive comorbid conditions at 
pretreatment was controlled for in Step 2. Results showed that pretreatment BDI-II scores 
accounted for a non-statistically significant proportion of variance in attrition (4.2%; see 
Table 7). Moreover, the adjusted odds ratio showed that for every one-point increase on 
the pretreatment BDI-II, the likelihood of attrition increased by 1.050 times (p = .154). In 
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other words, pretreatment depressive symptoms had a negligible impact on the likelihood 
of drop-out that is not statistically or clinically significant. 
Hypothesis 4 
 To test the hypothesis that greater severity of pretreatment depressive symptoms 
would predict treatment attendance, a hierarchical linear regression analysis was 
conducted using pretreatment BDI-II scores as the main independent variable and the 
total number of treatment sessions completed as the dependent variable. The full sample 
(N = 91) was included in the analysis. Pretreatment ADIS-IV scores were controlled for 
in Step 1 and the number of non-depressive comorbid conditions at pretreatment was 
controlled for in Step 2. The average number of treatment sessions completed was 12.55 
(SD = 3.643). Results showed that pretreatment BDI-II scores accounted for a negligible 
amount of variance in treatment attendance that was not statistically significant (0.8%; 
see Table 8). The results remained virtually unchanged when only those participants who 
had completed at least one session of treatment (n = 85) were included in the analysis. 
Discussion 
 The objectives of this study were twofold: to determine (1) if higher levels of 
depressive symptoms predicted poorer short- and long-term outcomes in an efficacious 
CBT program for GAD, and (2) if higher levels of pretreatment depressive symptoms 
predicted treatment non-engagement. Overall, our findings suggest that depressive 
symptoms do not substantially interfere with short or long-term treatment outcomes or 
with treatment engagement in this CBT program. Furthermore, our GAD treatment was 
successful at reducing both GAD and depressive symptomatology, despite not 
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specifically targeting depression. These gains were generally maintained over the follow-
up period. 
Predicting GAD at Posttreatment 
Of our four hypotheses, only one (Hypothesis 1) was partially supported 
statistically: greater pretreatment severity of depressive symptoms predicted greater 
posttreatment GAD severity as measured by the ADIS-IV, at a statistically significant 
level. In this analysis, pretreatment depressive symptom severity accounted for 7% of the 
variance in posttreatment ADIS-IV scores after controlling for pretreatment ADIS-IV 
scores and the total number of pretreatment non-depressive comorbid conditions. 
Although this finding is statistically significant, its clinical significance is dubious: the 
effect size is approximately half that of the effect sizes found in studies showing a 
statistically significant effect of depression on GAD treatment outcome (e.g., 12%, Crits-
Christoph et al., 2004) and social phobia treatment outcome (e.g., 15%, Marom et al., 
2009). Further, pre-treatment severity of depressive symptoms did not predict the 
posttreatment severity of worry (PSWQ) or somatic anxiety (WAQ-Som) at a statistically 
significant level. Overall, these results align with others in the extant literature finding 
little to no relation between depression severity and poorer short-term GAD treatment 
outcome (e.g., Newman et al., 2010; Wetherell et al., 2005). 
Although the severity of depression at pretreatment was mild in our sample (Mpre 
= 16.368, SDpre = 9.770), it is unlikely that this negatively affected its predictive power. 
Our sample’s pretreatment BDI scores are comparable to that of other studies 
investigating depressive symptoms and GAD (e.g., Butler, Fennell, Robson, & Gelder, 
1991: MBDI = 20.0, SDBDI = 9.3; Hopko et al., 2000: MBDI = 17.8, SDBDI = 6.7; Wetherell 
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et al., 2010: MBDI = 16.066, SDBDI = 6.83). Moreover, even subthreshold levels of 
depression at pretreatment have been shown to impact treatment outcomes in a variety of 
anxiety disorders (Rivas-Vasquez, Saffa-Biller, Ruiz, Blais, & Rivas-Vasquez, 2004). In 
sum, this suggests that the relatively low level of pretreatment depression in our sample is 
not responsible for the lack of findings. 
The finding that pretreatment depression severity predicts posttreatment GAD 
severity but not worry or somatic anxiety has several potential explanations, despite its 
dubious clinical significance. It suggests a differential relationship between depressive 
symptoms and GAD severity, worry, and somatic anxiety in the context of GAD 
treatment. This discrepant association between depressive symptoms and the measured 
GAD symptom dimensions could be due to: (1) instrument properties, (2) differential 
relationships among the constructs themselves, or (3) differential impact of depression on 
GAD treatment components. Each will be considered in turn. 
First, measurement modality may have affected the results of Hypothesis 1. The 
ADIS-IV is a clinician-rated questionnaire, whereas the PSWQ and WAQ-Som are self-
report questionnaires. Previous research suggests low (Beck, Stanley, & Zebb, 1995) to 
moderate (Hopko et al., 2000) associations between self- and clinician-rated measures of 
worry and anxiety. In our sample, the correlation between pretreatment ADIS-IV and 
PSWQ scores was moderate (r = .578, p = .010), as was the correlation between 
pretreatment ADIS-IV and WAQ-Som scores (r = .583, p = .010). Although simple 
correlations do not account for shared variances between these variables, they suggest 
that the measures may have sufficient differences to account for differential relationships 
with depression scores. 
  29 
Due to shared method variance, a stronger predictive relationship would be 
anticipated between the BDI-II and both the PSWQ and WAQ-Som, as these are all self-
report measures. Our findings stand in contrast to this, as statistically significant 
predictive relationships were not found between depression and worry or between 
depression and somatic anxiety. Examining the GAD outcome measures more closely, it 
is apparent that worry and somatic anxiety are captured in a very different way by their 
respective measures than is GAD severity by the ADIS-IV. The ADIS-IV assesses the 
presence of dysfunctional symptoms associated with GAD, impairment, distress, and the 
number of life domains affected. The PSWQ assesses the presence and degree of 
excessive worry, but does not directly assess associated impairment, distress, or the 
number of life domains affected. Similarly, the WAQ-SOM assesses self-rated severity of 
somatic anxiety symptoms, but does not directly measure impairment, distress or the 
number of life domains affected. The ADIS-IV is a closer approximation of Wakefield's 
(1992a) assertion that disorders are characterized by harmful dysfunction. Harmful 
dysfunction assumes that the disorder or condition (a) causes harm or deprivation of 
some benefit as judged by the values of the overarching culture and (b) causes an 
inability of a mental mechanism to perform its natural function. While distress, 
impairment, and the number of life domains affected are not sufficient measures of 
harmful dysfunction (Wakefield, 1992a; 1992b), the inclusion of these elements provides 
a closer approximation harmful dysfunction than their exclusion. Therefore, the ADIS-IV 
provides a more nuanced and valid assessment of the harmful dysfunction of GAD 
symptomatology than do the PSWQ and WAQ-Som. The BDI-II may have greater 
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predictive power of ADIS-IV scores relative to PSWQ and WAQ-Som scores due to this 
measurement difference. 
To test the possibility that the ADIS-IV provides a significantly different picture 
of GAD symptomatology than the other two measures, the same hierarchical regression 
analysis was conducted using another measure of overall GAD severity: the full scale of 
the WAQ. The WAQ, like the ADIS-IV, assesses DSM-IV criteria for overall GAD 
symptomatology and associated impairment. However, unlike the ADIS-IV, the WAQ 
does not directly measure associated distress or the number of life domains affected. 
Thus, I hypothesized it would function as a poorer approximation of harmful dysfunction 
(Wakefield, 1992a; 1992b) than the ADIS-IV. A hierarchical regression was conducted 
using pretreatment BDI-II scores and control variables to predict posttreatment scores on 
the full scale of the WAQ. The results of this analysis supported my assertion: 
pretreatment BDI-II scores did not predict posttreatment WAQ scores while controlling 
for pretreatment WAQ scores and the total number of non-depressive comorbid 
conditions at pretreatment. In sum, it is a strong possibility that the discrepant statistical 
findings regarding Hypothesis 1 are due to measurement modality. 
Second, the equivocal statistical relationship between pretreatment depression 
severity and posttreatment GAD measures could be due to the constructs themselves. 
That is, overall depression severity may relate more to overall GAD severity than to 
worry or somatic anxiety. Distinct elements of depression may relate differently to worry 
and somatic anxiety in the context of GAD treatment. For example, depressive 
rumination is a form of negative, repetitive thought implicated in intolerance of 
uncertainty (Yook, Kim, Suh, & Lee, 2010) and deficits in problem-solving (Donaldson, 
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& Lam, 2004). Rumination may better predict changes in worry across treatment as it is a 
highly related but separate construct (Goring & Papageorgiou, 2008). Similarly, somatic-
vegetative symptoms of depression overlap significantly with somatic anxiety symptoms 
(Menin et al., 2008). Although it is beyond the purview of the current study, the 
predictive power of rumination, somatic-vegetative depressive symptoms, hopelessness, 
and cognitive-affective depressive symptoms could be examined specifically in future 
research. 
 A third potential explanation for the Hypothesis 1 findings is that depressive 
symptom severity differentially impacts the components of GAD treatment. If this is true, 
it could attenuate the effect of depression severity on overall GAD treatment outcome. 
Given depression’s observed relationship with difficulties in problem-solving (Becker-
Weidman et al., 2010; Reinecke et al., 2001) and imaginal exposure (Dugas & 
Robichaud, 2007), these are the most likely treatment components that could be affected. 
A second possibility is that particular symptom dimensions of depression could 
differentially impact GAD treatment outcome. For example, the BDI-II appears to have a 
two-factor structure, organizing depressive symptoms into cognitive-affective and 
somatic-vegetative dimensions (Dozois, Dobson, & Ahnberg, 1998). It is possible that 
either factor could impact overall GAD treatment outcome or specific components. 
Neither of these possibilities could be investigated in our study due to lack of 
measurement of specific treatment components and issues of sample size, respectively. 
Future studies should examine the effects of depression on specific treatment components 
as well as the impact of specific depressive symptom dimensions on GAD treatment 
outcome. 
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 Overall, our current findings suggest that severity of depressive symptoms has 
minimal clinical impact on short-term GAD treatment outcome. However, the depression 
scores in our sample are lower than those of studies investigating GAD with depressive 
symptoms exclusively meeting DSM-IV criteria for MDD, such as Lawrence, Liverant, 
Rosellini, & Brown (2009): M = 26.89, SD = 9.58. This suggests our findings regarding 
short-term treatment outcome may only be representative of those with GAD and mild or 
subthreshold depressive symptoms. Further research is necessary to determine how 
moderate and severe comorbid depression may impact short- and long-term GAD 
treatment outcome. 
Predicting GAD at 18-Month Follow-Up 
 Our second hypothesis (Hypothesis 2) was not supported: the posttreatment 
severity of depressive symptoms did not predict the severity of overall GAD 
symptomatology, worry, or somatic anxiety at 18-month follow-up. This result coincides 
with the findings of several studies that found no effect of depressive symptoms on long-
term GAD treatment outcome (Newman et al., 2010; Wetherell et al., 2005). Although 
we had 6 available assessment points, ranging from 3 months posttreatment to 18-
months, this follow-up point was chosen because it is the most conservative in examining 
maintenance of treatment gains and therefore may be most clinically useful. A similar 
pattern of findings emerged when the same analyses used to test Hypothesis 2 were re-run 
using GAD outcome at all other available assessment points (3, 6, 9, 12, and 15 months 
posttreatment). Posttreatment depressive symptoms did not significantly predict ADIS-IV 
or PSWQ scores at any of the follow-up points, but accounted for a small amount of 
variance in WAQ-Som scores at 3-, 6-, and 9-month follow-ups. The finding that 
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depression is largely unrelated to GAD treatment outcome is supported by a number of 
studies in the available literature (Newman et al., 2010; Wetherell et al., 2005), although 
in contrast to our findings, these studies found that the presence of comorbid depression 
predicted improved outcomes. Only one study in the extant literature has examined a 
follow-up point beyond one year posttreatment (Newman et al., 2010); thus, the current 
study adds important information to existing research.  
 There are several potential explanations for the lack of support for Hypothesis 2.  
First, the sample’s depressive symptom severity was “minimal” by posttreatment (Mpost = 
8.234, SDpost = 8.374). This truncated range of scores may have decreased the predictive 
power of the BDI-II (Pagano, 2004). Although not explicitly targeted during treatment, 
depressive symptoms decreased a statistically significant amount from pre- to 
posttreatment. This suggests that at least some of the factors maintaining these depressive 
symptoms were alleviated, possibly due to symptom overlap, overlap with the 
maintaining factors of GAD, or the transfer of cognitive and behavioural techniques. If 
depressive symptoms and their maintaining factors were successfully reduced to the point 
of minimal impact on participants’ functioning, their power in predicting GAD severity 
18 months later would likely have been subsequently lessened. 
 Second, the lack of support for Hypothesis 2 could also be partially explained by 
additional statistical factors, such as issues with power and heteroscedasticity. Statistical 
power for this set of analyses may have been affected by the low sample size available at 
posttreatment (n = 47) combined with the number of predictors used. However, our data 
was within the suggested guidelines for adequate power. This set of analyses may also 
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have been affected by the heteroscedastic relationship between posttreatment depressive 
symptom severity and the GAD outcome measures at 18-month follow-up. 
 Third, it is possible that there is simply less to predict over the course of follow-
up as compared to the treatment period. One would expect, and indeed our data show, 
that there is greater change in GAD symptoms during the treatment period than across 
follow-ups. Impairment is highest at pretreatment and treatment actively targets these 
symptoms and their maintaining factors, leading to greater change during treatment than 
in the months subsequent to treatment. Furthermore, the follow-up period is associated 
with increased error due to the longer time period examined. This increased error 
combined with less change in GAD scores could be responsible for a significant decrease 
in the predictive power of depressive symptoms during the follow-up period. 
Predicting GAD Treatment Engagement 
 Our final major finding was that pretreatment severity of depressive symptoms 
did not predict treatment engagement, either in terms of attrition (Hypothesis 3) or 
treatment attendance (Hypothesis 4). Higher levels of pretreatment depressive symptoms 
did not significantly increase the likelihood of drop-out and did not significantly decrease 
the total number of treatment sessions completed. In other words, a participant’s odds of 
dropping out of the treatment program and the total number of treatment sessions they 
completed were not affected by how depressed they were at pretreatment. This stands in 
contrast to research suggesting that individuals with comorbid MDD and GAD have 
higher attrition rates (e.g., Brown et al., 1996), although there is a paucity of literature 
specifically regarding the relationship between GAD, comorbidity, and the number of 
treatment sessions completed. 
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 The possibility that depression severity has no relation to GAD treatment 
engagement is supported by the fact that comparable results were achieved when 
examining treatment engagement in two ways (i.e., number of sessions completed and 
drop-out status). This is complemented by our findings regarding short- and long-term 
GAD treatment outcome using measures of GAD symptom severity (Hypotheses 1 and 
2). Additionally, treatment motivation as measured by the Nijmegen Motivation List 2 
(Keijsers, Schaap, Hoogduin, Hoogsteyns, & de Kemp, 1999) was equivalent in 
individuals with the highest and lowest depression levels in our sample, as determined by 
a median split. Depression severity at pretreatment also did not predict treatment 
motivation in a hierarchical regression analysis when controlling for pretreatment GAD 
severity and the total number of comorbid conditions. In other words, depression severity 
had no relation to motivation to complete CBT for GAD. Perhaps this equivalency in 
treatment motivation partially accounts for the lack of relation between depression 
severity and treatment engagement. 
It is again of note that depression levels were considered “mild” in our sample at 
pretreatment. It is possible that these findings only represent the relationship between 
mild depressive symptoms and treatment engagement, given the relatively low severity of 
depressive symptoms in our sample at intake. Similar analyses would need to be 
conducted in samples with moderate to severe depressive symptoms in order to fully 
elucidate this relationship. 
Conclusions 
 Implications of findings. The severity of pretreatment depressive symptoms had 
little relation to short-term GAD treatment outcome: it was not predictive of the 
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posttreatment severity of worry and somatic anxiety, but accounted for a statistically 
significant amount of variance in posttreatment GAD severity. At this juncture the 
clinical significance of this finding appears to be negligible when examining GAD 
treatment in the aggregate. It remains unclear if this finding would be more pronounced if 
treatment components were examined separately or if the impact of different depressive 
symptom dimensions were examined. As it currently stands, our short-term treatment 
outcome finding has several clinical implications.  
First, it adds to the emerging literature demonstrating that depressive symptoms 
do not negatively impact short-term outcomes in CBT for GAD (Newman et al., 2010; 
Wetherell et al., 2005). However, our findings may only be generalizable to minimal and 
mild depressive symptoms. Second, depression severity appears to decrease over the 
course of GAD treatment even when not directly targeted. GAD and depression may have 
similar maintaining factors that decrease during manualized treatment for GAD. Third, 
GAD treatment outcome should be assessed using continuous and categorical methods. 
This provides a more complete picture of symptom change and treatment outcome. 
Finally, our findings do not suggest that our CBT protocol targeting GAD must be 
fundamentally changed or adjusted according to the level of depressive symptoms. It is 
possible that specific components of treatment are particularly susceptible to the 
influence of depressive symptoms, such as problem-solving training and imaginal 
exposure. However, further studies are necessary to determine the impact of depression 
on specific components of CBT protocols for GAD. 
 The finding that the severity of posttreatment depressive symptoms was not 
predictive of GAD symptoms at 18-month follow-up also has several implications. First, 
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it provides evidence of no effect of mild depressive symptoms on GAD outcome at a 
conservative, long-term assessment point. This adds further credence to the growing body 
of literature suggesting that comorbid depression does not predict poorer long-term GAD 
treatment outcome (Newman et al., 2010; Wetherell et al., 2005). Second, it suggests that 
individuals with residual depressive symptoms at posttreatment do not need to be offered 
a greater number of booster sessions across follow-ups than individuals without residual 
depressive symptoms in order to maintain their treatment gains. Third, it implies that it is 
not imperative to assess depressive symptoms at posttreatment, although this may only 
apply to samples with mild to minimal levels of depression. 
 Finally, the finding that the severity of pretreatment depressive symptoms does 
not predict treatment engagement in terms of either treatment attendance (i.e., total 
number of treatment sessions completed) or attrition also has several implications. First, 
it implies that individuals with concurrent, mild depressive symptoms do not need 
additional intervention or monitoring to improve treatment engagement or attendance. 
Second, it suggests that greater pretreatment severity of depressive symptoms does not 
interfere with motivation to complete GAD treatment, which was found to be true in a 
follow-up analysis. 
 Limitations and directions for future research. Although this study was designed 
with the limitations of previous research in mind, the current study has a number of 
limitations of its own. First, our sample was likely not representative of those with “pure” 
GAD, “pure” depressive disorders, or comorbid GAD/depression in the general 
population, due to both the nature of recruitment procedures and certain inclusion and 
exclusion criteria. For example, the exclusion of current suicidal ideation may be 
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problematic due to its frequency in GAD, clinically depressed, and comorbid 
GAD/depression populations (Sareen et al., 2005). Second, few participants in our 
sample met the clinical threshold for MDD or dysthymia (i.e., only 2 participants met 
diagnostic criteria). This may have had a detrimental impact on our observed effect sizes, 
despite the fact that subthreshold depressive symptoms have been shown to impact 
treatment outcome (Rivas-Vasquez et al., 2004). Further, this low level of depression 
may negatively impact the generalizability of our findings. Future research must examine 
the impact of moderate and severe depressive symptoms on GAD treatment outcome. 
Third, due to ongoing data collection substantially fewer participants had completed the 
18-month follow-up as compared to those who had completed the treatment program 
itself. Although our samples were within acceptable power limits for the analyses 
conducted, this may have affected the outcome of analyses examining GAD outcome at 
18-month follow-up. Fourth, we did not have a sufficient number of treatment completers 
to examine GAD outcome dichotomously either at posttreatment or at 18-month follow-
up. Although assessing GAD outcome in a continuous manner has significant benefits, 
assessing GAD remission status would also be informative. One advantage of a 
categorical approach is that it sorts participants into subgroups according to the severity 
of their symptoms, thus allowing us to bluntly examine treatment outcome in terms of 
remission and relapse. Another advantage of categorically assessing outcome is its 
consistency with the most widely used current classification systems – notably, the DSM-
IV and ICD-10 – and the extant literature. Thus, future investigations should assess GAD 
outcome both continuously and categorically to maximize the informative value of 
findings. Fifth, the current study included self-report and clinician-rated GAD outcome 
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measure, both of which may be subject to expectancy biases. Future studies should 
include behavioural or implicit measures if possible, as these are relatively free of such 
biases. Finally, dimensions of depressive symptoms (e.g., cognitive-affective or somatic-
vegetative) may differentially impact treatment outcome, a possibility that was not 
investigated in the present study. Similarly, depression may differentially affect 
components of CBT protocols, such as imaginal exposure and problem-solving training. 
Examining this differential impact would more effectively guide clinicians in monitoring 
and targeting problematic symptoms of depression during GAD treatment.
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Table 1 
Pretreatment BDI-II Scores Predicting Posttreatment ADIS-IV Scores 
 ∆R2 B SEB t-ratio df p 
Step 1 
 ADIS-IV pre-tx .099 0.542 0.188 2.885 76 .005 
Step 2 
 ADIS-IV pre-tx  0.537 0.198 2.708 
 No. comorbid cons .000 0.015 0.174 0.087 75 .931 
Step 3 
 ADIS-IV pre-tx  0.350 0.205 1.701 
 No. comorbid cons  0.041 0.169 0.243  
 BDI-II pre-tx .070 0.036 0.015 2.506 74 .014 
Note. “ADIS-IV pre-tx” is the pretreatment severity of overall GAD symptomatology as measured by the 
Anxiety Disorders Interview Schedule for DSM-IV, “No. comorbid cons” is the total number of non-
depressive comorbid conditions at pretreatment, and “BDI-II pre-tx” is the pretreatment severity of 
depressive symptoms as measured by the Beck Depression Inventory, 2nd Edition. 
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Table 2 
Pretreatment BDI-II Scores Predicting Posttreatment PSWQ Scores 
 ∆R2 B SEB t-ratio df p 
Step 1 
 PSWQ pre-tx .165 0.553 0.143 3.871 76 .000 
Step 2 
 PSWQ pre-tx  0.544 0.144 3.766 
 No. comorbid cons .003 0.715 1.341 0.533 75 .595 
Step 3 
 PSWQ pre-tx  0.477 0.150 3.175 
 No. comorbid cons  0.676 1.331 0.508  
 BDI-II pre-tx .024 0.172 0.117 1.475 74 .145 
Note. “PSWQ pre-tx” is the pretreatment severity of worry as measured by the Penn State Worry 
Questionnaire, “No. comorbid cons” is the total number of non-depressive comorbid conditions at 
pretreatment, and “BDI-II pre-tx” is the pretreatment severity of depressive symptoms as measured by the 
Beck Depression Inventory, 2nd Edition. 
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Table 3 
Pretreatment BDI-II Scores Predicting Posttreatment WAQ-Som Scores 
 ∆R2 B SEB t-ratio df p 
Step 1 
 WAQ-Som pre-tx .307 0.738 0.127 5.803 76 .000 
Step 2 
 WAQ-Som pre-tx  0.716 0.125 5.710 
 No. comorbid cons .034 1.061 0.536 1.979 75 .051 
Step 3 
 WAQ-Som pre-tx  0.696 0.136 5.103 
 No. comorbid cons  1.057 0.539 1.959  
 BDI-II pre-tx .001 0.018 0.049 0.375 74 .709 
Note. “WAQ-Som pre-tx” is the pretreatment severity of somatic anxiety as measured by the Somatic 
subscale of the Worry and Anxiety Questionnaire, “No. comorbid cons” is the total number of non-
depressive comorbid conditions at pretreatment, and “BDI-II pre-tx” is the pretreatment severity of 
depressive symptoms as measured by the Beck Depression Inventory, 2nd Edition. 
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Table 4 
Posttreatment BDI-II Scores Predicting ADIS-IV Scores at 18-Month Follow-Up 
 ∆R2 B SEB t-ratio df p 
Step 1 
 ADIS-IV post-tx .332 0.840 0.178 4.726 45 .000 
Step 2 
 ADIS-IV post-tx  0.775 0.180 4.300 
 No. comorbid cons .033 0.386 0.256 1.505 44 .139 
Step 3 
 ADIS-IV post-tx  0.702 0.241 2.911 
 No. comorbid cons  0.379 0.259 1.462  
 BDI-II post-tx .003 0.014 0.031 0.465 43 .644 
Note. “ADIS-IV post-tx” is the posttreatment severity of overall GAD symptomatology as measured by the 
Anxiety Disorders Interview Schedule for DSM-IV, “No. comorbid cons” is the total number of non-
depressive comorbid conditions at posttreatment, and “BDI-II post-tx” is the posttreatment severity of 
depressive symptoms as measured by the Beck Depression Inventory, 2nd Edition. 
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Table 5 
Posttreatment BDI-II Scores Predicting PSWQ Scores at 18-Month Follow-Up 
 ∆R2 B SEB t-ratio df p 
Step 1 
 PSWQ post-tx .513 0.899 0.131 6.884 45 .000 
Step 2 
 PSWQ post-tx  0.841 0.127 6.603 
 No. comorbid cons .052 3.507 1.530 2.292 44 .027 
Step 3 
 PSWQ post-tx  0.793 0.146 5.424 
 No. comorbid cons  3.379 1.550 2.179  
 BDI-II post-tx .005 0.108 0.158 0.686 43 .497 
Note. “PSWQ post-tx” is the posttreatment severity of worry as measured by the Penn State Worry 
Questionnaire, “No. comorbid cons” is the total number of non-depressive comorbid conditions at 
posttreatment, and “BDI-II post-tx” is the posttreatment severity of depressive symptoms as measured by 
the Beck Depression Inventory, 2nd Edition. 
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Table 6 
Posttreatment BDI-II Scores Predicting WAQ-Som Scores at 18-Month Follow-Up 
 ∆R2 B SEB t-ratio df p 
Step 1 
 WAQ-Som post-tx .386 0.741 0.139 5.317 45 .000 
Step 2 
 WAQ-Som post-tx  0.617 0.151 4.092 
 No. comorbid cons .046 1.566 0.828 1.890 44 .065 
Step 3 
 WAQ-Som post-tx  0.554 0.165 3.362 
 No. comorbid cons  1.557 0.829 1.878  
 BDI-II post-tx .012 0.071 0.075 0.956 43 .345 
Note. “WAQ-Som post-tx” is the posttreatment severity of somatic anxiety as measured by the Somatic 
subscale of the Worry and Anxiety Questionnaire, “No. comorbid cons” is the total number of non-
depressive comorbid conditions at posttreatment, and “BDI-II post-tx” is the posttreatment severity of 
depressive symptoms as measured by the Beck Depression Inventory, 2nd Edition. 
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Table 7 
Pretreatment BDI-II Scores Predicting Drop-Out Status at Posttreatment 
 Negelkerke ∆R2 B SEB Wald Exp(B) p 
Step 1 
 ADIS-IV pre-tx .000 -0.016 0.426 0.001 0.984 .970 
Step 2 
 ADIS-IV pre-tx  -0.032 0.446 0.005 0.969 .943 
 No. comorbid cons .000 0.047 0.397 0.014 1.048 .906 
Step 3 
 ADIS-IV pre-tx  -0.283 0.492 0.331 0.753 .565 
 No. comorbid cons  0.074 0.394 0.035 1.076 .852 
 BDI-II pre-tx .042 0.049 0.034 2.035 1.050 .154 
Note. “ADIS-IV pre-tx” is the pretreatment severity of overall GAD symptomatology as measured by the 
Anxiety Disorders Interview Schedule for DSM-IV, “No. comorbid cons” is the total number of non-
depressive comorbid conditions at pretreatment, and “BDI-II pre-tx” is the pretreatment severity of 
depressive symptoms as measured by the Beck Depression Inventory, 2nd Edition. 
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Table 8 
Pretreatment BDI-II Scores Predicting Number of Treatment Sessions Completed 
 ∆R2 B SEB t-ratio df p 
Step 1 
 ADIS-IV pre-tx .003 0.260 0.528 0.492 89 .624 
Step 2 
 ADIS-IV pre-tx  0.304 0.557 0.546 
 No. comorbid cons .001 -0.130 0.498 -0.262 88 .794 
Step 3 
 ADIS-IV pre-tx  0.463 0.588 0.787 
 No. comorbid cons  -0.136 0.499 -0.272 
 BDI-II pre-tx .008 -0.037 0.043 -0.854 87 .395 
Note. “ADIS-IV pre-tx” is the pretreatment severity of overall GAD symptomatology as measured by the 
Anxiety Disorders Interview Schedule for DSM-IV, “No. comorbid cons” is the total number of non-
depressive comorbid conditions at pretreatment, and “BDI-II pre-tx” is the pretreatment severity of 
depressive symptoms as measured by the Beck Depression Inventory, 2nd Edition. 
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Appendix B 
CONSENT FORMS FOR STUDY PARTICIPATION 







Formulaire d’information et de consentement téléphonique 
(1e partie : Évaluation de l’admissibilité) 
 
Titre de l’étude :  La thérapie cognitivo-comportementale pour le trouble d’anxiété généralisée : 
Impact du traitement de l’information sur l’efficacité thérapeutique à court et à long terme  
 
Chercheur principal :  Michel Dugas, Ph.D. Professeur titulaire, Université Concordia 
      Chercheur, Centre de recherche HSCM 
 
INFORMATION 
A. BUT DE L’ÉTUDE 
Le but de cette étude est d’évaluer l’impact des biais de traitement de l’information sur l’efficacité à court 
et à long terme de la thérapie cognitivo-comportementale pour le trouble d’anxiété généralisée (TAG). La 
première partie de l’étude consiste à évaluer de façon préliminaire la nature et la sévérité de vos symptômes 
anxieux afin de déterminer si vous rencontrez les critères de sélection pour passer à la seconde étape 
d’évaluation et par la suite recevoir le traitement pour le trouble d’anxiété généralisée. 
 
B. PROCÉDURES 
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Dans un premier temps, vous participerez à une entrevue d’évaluation téléphonique (durée 1h30) avec une 
psychologue de l’équipe. 
S’il semble que vous rencontrez les critères de sélection de l’étude, vous serez référé(e) à la Clinique des 
troubles anxieux de l’Hôpital du Sacré-Cœur de Montréal, où vous serez évalué(e) à nouveau par un(e) 
psychiatre de notre équipe. Cette évaluation se déroule en personne et est d’une durée d’une heure trente 
environ.  Après cette rencontre, les membres de l’équipe de recherche (psychologues, psychiatres et 
chercheur principal) se réunissent pour discuter et vérifier si vous rencontrez bien les critères requis pour 
l’étude.  Nous vous ferons ensuite part de la décision de l’équipe. 
Si vous rencontrez les critères pour être inclus(e) dans l’étude, vous aurez à signer un autre formulaire de 
consentement concernant la suite de l’étude.   
 
C. RISQUES ET BÉNÉFICES 
 1. Risques, effets secondaires et désagréments 
Il n’est pas impossible que certaines questions provoquent un léger malaise à court terme (possiblement en 
vous faisant réfléchir à vos difficultés). Par contre, cette entrevue a déjà été utilisée à plusieurs reprises 
auprès des personnes anxieuses et les malaises sont rares. Si cela vous arrive, nous vous prions d’en 
discuter avec nous. 
 2. Bénéfices et avantages 
En participant à cette étude, vous bénéficierez d’une évaluation détaillée de votre état. Évidemment, si vous 
rencontrez les critères de sélection pour l’étude de traitement, vous recevrez une psychothérapie efficace 
pour le traitement du TAG. Parallèlement, vous pourrez contribuer à l’avancement des connaissances en 
participant à cette étude. 
 
D. CONDITIONS DE PARTICIPATION 
1. Versement d’une indemnité 
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Vous ne recevrez aucune rémunération pour votre participation à ce volet d’évaluation. 
 
2. Confidentialité 
Tous les renseignements recueillis à votre sujet demeureront strictement confidentiels, dans les limites 
prévues par la loi, et vous ne serez identifié(e) que par un code. 
3. Indemnisation en cas de préjudice 
En acceptant de participer à cette étude, vous ne renoncez à aucun de vos droits et vous ne libérez pas les 
chercheurs, l’organisme subventionnaire (Instituts de recherche en santé du Canada) ou les établissements 
impliqués de leurs responsabilités légales et professionnelles. 
4. Participation volontaire et retrait de l’étude 
Votre participation à cette étude est volontaire. Vous êtes donc libre de refuser d’y participer. Vous pouvez 
également vous retirer de l’étude à n’importe quel moment, sans avoir à donner de raisons, en faisant 















o Je comprends que je donne mon consentement verbal pour que l’équipe de recherche évalue si je 
rencontre les critères de sélection de l’étude. 
o Je comprends que je peux retirer mon consentement et interrompre ma participation à tout 
moment, sans conséquences négatives. 
o Je comprends que ma participation à cette étude est CONFIDENTIELLE (c.-à-d. les membres de 
l’équipe connaissent mon identité mais ne la révéleront pas). 
 
J’AI ÉCOUTÉ ATTENTIVEMENT CE QUI M’A ÉTÉ LU ET JE COMPRENDS LA NATURE DE 
CETTE ÉTUDE:  OUI_____ NON_____ 
 
JE CONSENS DONC VERBALEMENT, DE FAÇON LIBRE ET VOLONTAIRE À PARTICIPER À 
L’ÉVALUATION TÉLÉPHONIQUE ET S’IL Y A LIEU À LA RENCONTRE AVEC UN(E) 
PSYCHIATRE DE L’ÉQUIPE : 
   OUI_____ NON_____ 
 
NOM DU PARTICIPANT : _______________________________________  DATE : _____________ 
NOM DU MEMBRE DE L’ÉQUIPE : _______________________________  HEURE : ___________ 
SIGNATURE      DATE  ____________________________ 
Si vous avez des questions à poser au sujet de cette étude, vous pouvez contacter en tout temps la direction 
générale de l’Hôpital du Sacré-Cœur de Montréal au (514) 338-2222, poste 3581. 







FORMULAIRE D’INFORMATION ET DE CONSENTEMENT 
 
Titre de l’étude: La thérapie cognitivo-comportementale pour le trouble d’anxiété généralisée : 
Impact du traitement de l’information sur l’efficacité thérapeutique à court et à long terme 
 
Chercheur: Michel Dugas, Ph.D. (psychologie) 
  Chercheur régulier, Centre de recherche, HSCM 
  Psychologue, Clinique des troubles anxieux, HSCM 
  Professeur titulaire, Département de psychologie, Université Concordia 
  Tél : 514-338-4201 ou 514-848-2424 (poste 2215) 
  Courriel : Michel.Dugas@concordia.ca 
 
Co-chercheurs: Adam Radomsky, Ph.D. (psychologie) 
  Professeur adjoint, Département de psychologie, Université Concordia 
  Tél : 514-848-2424 (poste 2202) 
 Natalie Phillips, Ph.D. (psychologie) 
  Professeur agrégé, Département de psychologie, Université Concordia 
  Tél : 514-848-2424 (poste 2218) 
 William Bukowski, Ph.D. (psychologie) 
  Professeur titulaire, Département de psychologie, Université Concordia 
  Tél : 514-848-2424 (poste 2184) 
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 Julie Turcotte, M.D. (psychiatrie) 
  Professeur adjoint, Département de psychiatrie, 
  Faculté de Médecine, Université de Montréal 
  Psychiatre, Clinique des troubles anxieux, HSCM 
  Tél : 514-338-4201 
 Pierre Savard, M.D., Ph.D. (microbiologie et immunologie) 
  Professeur adjoint, Département de psychiatrie, 
  Faculté de Médecine, Université de Montréal 
  Psychiatre, Clinique des troubles anxieux, HSCM 
  Tél : 514-338-4201 
 Adrienne Gaudet, M.D. (psychiatrie) 
  Professeur adjoint, Département de psychiatrie, 
  Faculté de Médecine, Université de Montréal 
  Psychiatre, Clinique des troubles anxieux, HSCM 
  Tél : 514-338-4201 
Organisme  
de subvention : Instituts de recherche en santé du Canada  
  410 avenue Laurier ouest, 9ème étage, indice de l’adresse 4209A, 
  Ottawa, Ontario, K1A 0W9 
 
INFORMATION 
1. Nature et objectif de l’étude 
Nous savons aujourd’hui que les personnes atteintes de troubles anxieux ont certains biais dans leur façon 
de traiter l’information provenant de leur environnement. Par exemple, les personnes anxieuses tendent à 
porter leur attention plus rapidement à certains « signes de danger » et à interpréter certaines situations 
ambiguës de façon menaçante. Par contre, nous ne savons pas si l’ampleur de ces biais affecte la réponse à 
la psychothérapie. En d’autres mots, nous ne savons pas si les personnes anxieuses qui présentent des biais 
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plus importants dans leur façon de traiter l’information répondent différemment aux interventions 
psychologiques. 
Le but de cette étude est d’évaluer l’impact des biais de traitement de l’information sur l’efficacité à court 
et à long terme de la thérapie cognitivo-comportementale pour le trouble d’anxiété généralisée (TAG). Plus 
particulièrement, nous voulons : (1) évaluer l’impact des biais « pré-thérapie » sur la réponse à cette 
thérapie; et (2) évaluer l’impact des biais « post-thérapie » sur le maintien des gains thérapeutiques suite à 
la thérapie. Afin d’évaluer l’ampleur des biais de traitement de l’information, nous nous proposons 
d’utiliser trois tâches informatiques qui sont expliquées ci-dessous. 
 
Cent dix (110) adultes avec un diagnostic principal de trouble d’anxiété généralisée participeront à cette 
étude. Les participants seront recrutés à la Clinique des troubles anxieux de l’Hôpital du Sacré-Cœur de 
Montréal ou par le biais d’annonces placées dans le quotidien La Presse. 
 
2. Déroulement de l’étude et méthodes utilisées 
Les grandes lignes pour la suite de l’étude sont les suivantes : (1) évaluation pré-thérapie en deux 
rencontres; (2) thérapie cognitivo-comportementale administrée en 14 rencontres hebdomadaires; (3) 
évaluation post-thérapie en huit rencontres sur une période de 18 mois.  
 
Premier volet : Évaluation pré-thérapie 
Suite à l’évaluation de vos symptômes d’anxiété – entrevues téléphoniques et entrevue psychiatrique à la 
Clinique des troubles anxieux – nous avons déterminé que vous rencontrez les critères d’inclusion de cette 
étude. Vous participerez maintenant à une rencontre d’environ deux heures avec une psychologue de notre 
équipe (Isabelle Geninet, Pascale Harvey ou Amélie Seidah) – le but de cette rencontre est d’évaluer vos 
traits de personnalité ou votre façon habituelle de réagir aux événements de tous les jours. Au cours de cette 
rencontre, vous aurez aussi à compléter des questionnaires portant sur vos symptômes d’anxiété. Par la 
suite, vous aurez à participer à une dernière rencontre d’évaluation pendant laquelle vous ferez trois tâches 
sur un ordinateur et répondrez à des questionnaires. En ce qui concerne les tâches informatiques, vous ferez 
une tâche évaluant votre façon de porter attention à certains mots et deux tâches évaluant votre façon de 
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comprendre certaines situations. Chacune des trois tâches prend environ 20 minutes à compléter. Vous 
répondrez ensuite à des questionnaires qui ont pour but d’évaluer votre état général. Cela vous prendra 
environ 20 minutes pour répondre aux questionnaires. La durée totale de cette rencontre (directives, tâches 
informatiques, pause et questionnaires) sera d’environ une heure et demie. 
 
Deuxième volet : Thérapie cognitivo-comportementale 
En participant à cette étude, vous recevrez une psychothérapie efficace pour le traitement du TAG. Cette 
thérapie, de type cognitivo-comportementale, pourrait vous aider à comprendre et à changer les 
comportements et pensées qui contribuent à vos difficultés. La durée de cette thérapie est de quatre mois 
(14 rencontres hebdomadaires de 50 minutes) et elle vous sera administrée par une des psychologues de 
notre équipe. Entre les rencontres, vous aurez des lectures à faire et des exercices à pratiquer. 
 
Troisième volet : Évaluation post-thérapie 
Afin d’évaluer les effets de la psychothérapie à long terme, vous serez évalué(e) à sept reprises, sur une 
période de 18 mois, suite à votre thérapie. Immédiatement après la thérapie, vous participerez à deux 
rencontres d’évaluation (rencontre 1 : entrevue diagnostique et questionnaires; rencontre 2 : tâches à 
l’ordinateur et questionnaires). Par la suite, vous participerez à une rencontre d’évaluation (entrevue 
diagnostique et questionnaires) à six reprises, c’est-à-dire aux relances de 3, 6, 9, 12, 15 et 18 mois. 
 
 
3. Risques, effets secondaires et désagréments 
Évaluations 
Il n’est pas impossible que certaines tâches ou certains questionnaires provoquent un léger malaise à court 
terme (possiblement en vous faisant réfléchir à vos difficultés). Par contre, ces tâches et questionnaires ont 
déjà été utilisés à plusieurs reprises auprès des personnes anxieuses et les malaises sont rares. Si cela vous 
arrive, nous vous prions d’en discuter avec la professionnelle de recherche ou avec votre thérapeute. 
 
 




Il est possible que quelques uns des exercices prescrits par votre psychologue provoquent certains malaises 
à court terme. Ceux-ci sont temporaires et disparaissent habituellement avec la pratique répétée de ces 
exercices. 
 
Si vous recevez un médicament de votre médecin ou de votre psychiatre au moment du début de l’étude, 
cela demeure la responsabilité de ce dernier pendant la durée du traitement. Cependant, nous vous 
demandons seulement de ne pas augmenter le dosage de votre médication ou de modifier le type de 
médicament sans en avertir préalablement votre thérapeute. 
 
4. Bénéfices et avantages 
Tel que mentionné précédemment, en participant à cette étude, vous recevrez une psychothérapie efficace 
pour le traitement du TAG. De plus, cette thérapie vous sera offerte par des psychologues qui sont des 
experts dans son application. Vous profiterez aussi d’une évaluation plus poussée de votre état, avec un 
suivi sur une période de 18 mois après la fin de la psychothérapie. Parallèlement, vous allez nous aider à 
mieux évaluer les facteurs qui influencent l’efficacité de cette thérapie et ainsi contribuer à l’avancement 
des connaissances en participant à cette étude. 
 
5. Versement d’une indemnité 
Vous ne recevrez aucune rémunération pour votre participation à la première partie de cette étude 
(évaluation pré-thérapie, psychothérapie et évaluation immédiatement après la thérapie). Par contre, vous 
recevrez une compensation de 30$ pour chacune des six rencontres de relance (3, 6, 9, 12, 15 et 18 mois 
après la fin de la psychothérapie). Donc, si vous vous présentez pour toutes les rencontres de relances, vous 
recevrez une indemnité de 180$. 
 
6. Confidentialité 
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Tous les renseignements recueillis à votre sujet au cours de l’étude demeureront strictement confidentiels, 
dans les limites prévues par la loi, et vous ne serez identifié(e) que par un code. Les rencontres avec les 
psychologues seront enregistrées sur cassettes audio afin de nous permettre d’évaluer la qualité des 
interventions offertes par celles-ci (les cassettes seront aussi identifiées par un code). Immédiatement après 
l’étude, toutes les cassettes seront détruites. Aucune publication ou communication scientifique résultant de 
cette étude ne renfermera quoi que ce soit qui puisse permettre de vous identifier. 
 
Cependant, à des fins de contrôle du projet de recherche, votre dossier pourra être consulté par une 
personne mandatée par le comité d’éthique de la recherche de l’Hôpital du Sacré-Cœur ainsi que par des 
représentants de l’organisme de subvention (Instituts de recherche en santé du Canada). Tous ces 
organismes adhèrent à une politique de stricte confidentialité. 
 
7. Indemnisation en cas de préjudice 
Si vous deviez subir quelque préjudice que ce soit résultant de votre participation à cette étude, vous 
recevrez tous les soins médicaux nécessaires, sans frais de votre part. Toutefois, ceci ne vous empêche 
nullement d’exercer un recours légal en cas de faute reprochée à toute personne impliquée dans l’étude. 
 
En acceptant de participer à cette étude, vous ne renoncez à aucun de vos droits ni ne libérez les chercheurs, 
l’organisme subventionnaire (Instituts de recherche en santé du Canada) ou les établissements impliqués de 
leurs responsabilités légales et professionnelles. 
 
8. Participation volontaire et retrait de l’étude 
Votre participation à cette étude est volontaire. Vous êtes donc libre de refuser d’y participer. Vous pouvez 
également vous retirer de l’étude à n’importe quel moment, sans avoir à donner de raisons, en faisant 
connaître votre décision au chercheur ou à l’un des membres de l’équipe de recherche. Toute nouvelle 
connaissance acquise durant le déroulement de l’étude qui pourrait affecter votre décision de continuer d’y 
participer vous sera communiquée sans délai. 
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Votre décision de vous en retirer n’aura aucune conséquence sur les soins qui vous seront fournis par la 
suite ou sur vos relations avec votre médecin et les autres intervenants. 
9. Personnes à contacter 
Si vous avez des questions à poser au sujet de cette étude ou s’il survient un incident quelconque ou si vous 
désirez vous retirer de l’étude, vous pouvez contacter en tout temps le Dr Michel Dugas (le chercheur 
principal de l’étude) aux numéros de téléphone suivants :  
 
Lundi, mardi, jeudi et vendredi : (514) 848-2424, poste 2215 (Département de psychologie, Université 
Concordia)  
Mercredi : (514) 338-4201 (Clinique des troubles anxieux, Hôpital du Sacré-Cœur) 
 
Si vous voulez poser des questions à un professionnel ou à un chercheur qui n’est pas impliqué dans cette 
étude, vous pouvez communiquer avec Dr. Normand Lussier, omnipraticien à la Clinique des troubles 
anxieux, au (514) 338-4201. 
 
Si vous avez des questions à poser concernant vos droits en tant que participant à un projet de recherche, ou 
si vous avez des plaintes ou des commentaires à formuler, vous pouvez communiquer avec la direction 
générale de l’hôpital, au (514) 338-2222, poste 3581. 






La thérapie cognitivo-comportementale pour le trouble d’anxiété généralisée : Impact du traitement de 
l’information sur l’efficacité thérapeutique à court et à long terme 
La nature de cette étude, les procédés à utiliser, les risques et les bénéfices que comporte ma participation à 
cette étude ainsi que le caractère confidentiel des informations qui seront recueillies au cours de l’étude 
m’ont été expliqués. 
 
J’ai eu l’occasion de poser toutes mes questions concernant les différents aspects de cette étude et on y a 
répondu à ma satisfaction. 
 
Je reconnais qu’on m’a laissé le temps voulu pour prendre ma décision. 
 
J’accepte volontairement de participer à cette étude. Je demeure libre de m’en retirer en tout temps sans que 
cela ne nuise aux relations avec mon médecin ou les autres intervenants et sans préjudice d’aucune sorte. 
 
Je recevrai une copie signée de ce formulaire d’information et de consentement. 
 
_____________________________ _____________________________ ______________ 
Nom du sujet    Signature    Date 
(en lettres moulées) 
 
 
_____________________________ _____________________________ ______________ 
Nom du chercheur   Signature    Date 
ou de son représentant 
(en lettres moulées) 
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Appendix D 
THE WORRY AND ANXIETY QUESTIONNAIRE (WAQ) 
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Appendix E 
THE PENN STATE WORRY QUESTIONNAIRE (PSWQ) 
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QIPS
No. Dossier ________ Date _______________
Pas du Un peu Assez Très Extrêmement
tout corres- corres- corres- corres- corres-
pondant pondant pondant pondant pondant
1. Si je n'ai pas assez de temps pour
tout faire, je ne m'inquiète pas.    ....................................1....................2.............................3...............................4................................5................
2. Mes inquiétudes me submergent.    .........................1....................2.............................3...............................4................................5................
3. Je n'ai pas tendance à m'inquiéter
à propos des choses.    ..........................................1....................2.............................3...............................4................................5................
4. Plusieurs situations 
m'amènent à m'inquiéter.    .....................................1....................2.............................3...............................4................................5................
5. Je sais que je ne devrais pas
m'inquiéter mais je n'y peux rien.    .................................1....................2.............................3...............................4................................5................
6. Quand je suis sous pression,
je m'inquiète beaucoup.    .............................................1....................2.............................3...............................4................................5................
7. Je m'inquiète continuellement 
à propos de tout.    ................................................1....................2.............................3...............................4................................5................
8. Il m'est facile de me débarrasser 
de pensées inquiétantes.    ......................................1....................2.............................3...............................4................................5................
QIPS
Veuillez utiliser l'échelle ci-dessous pour exprimer jusqu'à quel point chacun des énoncés suivants correspond 
à vous.  Encerclez le numéro (1 à 5) approprié.
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Pas du Un peu Assez Très Extrêmement
tout corres- corres- corres- corres- corres-
pondant pondant pondant pondant pondant
9. Aussitôt que j'ai fini une tâche, je 
commence immédiatement à 
m'inquiéter au sujet de toutes les
autres choses que j'ai encore à faire. ..............1....................2.............................3...............................4................................5................
10. Je ne m'inquiète jamais.    .......................................1....................2.............................3...............................4................................5................
11. Quand je n'ai plus rien à faire au sujet 
d'un tracas, je ne m'en inquiète plus. ..............1....................2.............................3...............................4................................5................
12. J'ai été inquiet tout au long de ma vie. ..............1....................2.............................3...............................4................................5................
13. Je remarque que je m'inquiète 
pour certains sujets.    ............................................1....................2.............................3...............................4................................5................
14. Quand je commence à m'inquiéter, 
je ne peux pas m'arrêter.    .....................................1....................2.............................3...............................4................................5................
15. Je m'inquiète tout le temps.     .......................................1....................2.............................3...............................4................................5................
16. Je m'inquiète au sujet de mes projets 
jusqu'à ce qu'ils soient complétés.    ..................................1....................2.............................3...............................4................................5................
Version française: Ladouceur, R., Freeston, M.H., Dumont, J. Letarte, H., Rhéaume, J. Thibodeau, N. & Gagnon, F. (1992).
Canadian Psychology/ Psychologie Canadienne, 33,  240.
Version originale: Meyer, T.J., Miller, M.L., Metzger, R.L., & Borkovec, T.D.  (1990).  Behaviour Research and Therapy, 28 , 487-495. 
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THE BECK DEPRESSION INVENTORY, 2nd EDITION (BDI-II)
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IDB-II
1.
0 Je ne me sens pas triste.
1 Je me sens très souvent triste.
2 Je suis tout le temps triste.
3 Je suis si triste ou si malheureux(se), que ce n'est pas supportable.
2.
0 Je ne suis pas découragé(e) face à mon avenir.
1 Je me sens plus découragé(e) qu'avant face à mon avenir.
2 Je ne m'attends pas à ce que les choses s'arrangent pour moi.
3 J'ai le sentiment que mon avenir est sans espoir et qu'il ne peut qu'empirer.
3.
0 Je n'ai pas le sentiment d'avoir échoué dans la vie, d'être un(e) raté(e).
1 J'ai échoué plus souvent que je n'aurais dû.
2 Quand je pense à mon passé, je constate un grand nombre d'échecs.
3 J'ai le sentiment d'avoir complètement raté ma vie.
4.
0 J'éprouve toujours autant de plaisir qu'avant aux choses qui me plaisent.
1 Je n'éprouve pas autant de plaisir aux choses qu'avant.
2 J'éprouve très peu de plaisir aux choses qui me plaisaient habituellement.
3 Je n'éprouve aucun plaisir aux choses qui me plaisaient habituellement.
5.
0 Je ne me sens pas particulièrement coupable.
1 Je me sens coupable pour bien des choses que j'ai faites ou que j'aurais dû faire.
2 Je me sens coupable la plupart du temps.
3 Je me sens tout le temps coupable.
IDB-II
No. Dossier ________ Date _____________
Ce questionnaire comporte 21 groupes d'énoncés. Veuillez lire avec soin chacun de ces groupes puis,  
Assurez-vous bien de ne choisir qu'un seul énoncé dans chaque groupe, y compris le groupe no. 16 
(modifications dans les habitudes de sommeil) et le groupe no. 18 (modifications de l'appétit).
dans chaque groupe, choisissez l'énoncé qui décrit le mieux comment vous vous êtes senti(e) au cours
des deux dernières semaines, incluant aujourd'hui. Encerclez alors le chiffre placé devant 
l'énoncé que vous avez choisi. Si, dans un groupe d'énoncés, vous en trouvez plusieurs qui semblent décrire
également bien ce que vous ressentez, choisissez celui qui a le chiffre le plus élevé et encerclez ce chiffre. 
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6.
0 Je n'ai pas le sentiment d'être puni(e).
1 Je sens que je pourrais être puni(e).
2 Je m'attends à être puni(e).
3 J'ai le sentiment d'être puni(e).
7.
0 Mes sentiments envers moi-même n'ont pas changé.
1 J'ai perdu confiance en moi.
2 Je suis déçu(e) par moi-même.
3 Je ne m'aime pas du tout.
8.
0 Je ne me blâme pas ou ne me critique pas plus que d'habitude.
1 Je suis plus critique envers moi-même que je ne l'étais.
2 Je me reproche tous mes défauts.
3 Je me reproche tous les malheurs qui arrivent.
9.
0 Je ne pense pas du tout à me suicider.
1 Il m'arrive de penser à me suicider, mais je ne le ferais pas.
2 J'aimerais me suicider.
3 Je me suiciderais si l'occasion se présentait.
10.
0 Je ne pleure pas plus qu'avant.
1 Je pleure plus qu'avant.
2 Je pleure pour la moindre petite chose.
3 Je voudrais pleurer mais je n'en suis pas capable.
11.
0 Je ne suis pas plus agité(e) ou plus tendu(e) que d'habitude.
1 Je me sens plus agité(e) ou plus tendu(e) que d'habitude.
2 Je suis si agité(e) ou tendu(e) que j'ai du mal à rester tranquille.
3 Je suis si agité(e) ou tendu(e) que je dois continuellement bouger ou faire quelque chose.
12.
0 Je n'ai pas perdu d'intérêt pour les gens ou pour les activités.
1 Je m'intéresse moins qu'avant aux gens et aux choses.
2 Je ne m'intéresse presque plus aux gens et aux choses.
3 J'ai du mal à m'intéresser à quoi que se soit.
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13.
0 Je prends des décisions toujours aussi bien qu'avant.
1 Il m'est plus difficile que d'habitude de prendre des décisions.
2 J'ai beaucoup plus de mal qu'avant à prendre des décisions.
3 J'ai du mal à prendre n'importe quelle décision.
14.
0 Je pense être quelqu'un de valable.
1 Je ne crois pas avoir autant de valeur ni être aussi utile qu'avant.
2 Je me sens moins valable que les autres.
3 Je sens que je ne vaux absolument rien.
15.
0 J'ai toujours autant d'énergie qu'avant.
1 J'ai moins d'énergie qu'avant.
2 Je n'ai pas assez d'énergie pour pouvoir faire grand-chose.
3 J'ai trop peu d'énergie pour faire quoi que ce soit.
16.
0 Mes habitudes de sommeil n'ont pas changé.
1a Je dors un peu plus que d'habitude.
1b Je dors un peu moins que d'habitude.
2a Je dors beaucoup plus que d'habitude.
2b Je dors beaucoup moins que d'habitude.
3a Je dors presque toute la journée.
3b Je me réveille une ou deux heures plus tôt et je suis incapable de me rendormir.
17.
0 Je ne suis pas plus irritable que d'habitude.
1 Je suis plus irritable que d'habitude.
2 Je suis beaucoup plus irritable que d'habitude.
3 Je suis constamment irritable.
18.
0 Mon appétit n'a pas changé.
1a J'ai un peu moins d'appétit que d'habitude.
1b J'ai un peu plus d'appétit que d'habitude.
2a J'ai beaucoup moins d'appétit que d'habitude.
2b J'ai beaucoup plus d'appétit que d'habitude.
3a Je n'ai pas d'appétit du tout.
3b J'ai constamment envie de manger.
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19.
0 Je parviens à me concentrer toujours aussi bien qu'avant.
1 Je ne parviens pas à me concentrer aussi bien que d'habitude.
2 J'ai du mal à me concentrer longtemps sur quoi que ce soit.
3 Je me trouve incapable de me concentrer sur quoi que ce soit.
20.
0 Je ne suis pas plus fatigué(e) que d'habitude.
1 Je me fatigue plus facilement que d'habitude.
2 Je suis trop fatigué(e) pour faire un grand nombre de choses que je faisais avant.
3 Je suis trop fatigué(e) pour faire la plupart des choses que je faisais avant.
21.
0 Je n'ai pas noté de changement récent dans mon intérêt pour le sexe.
1 Le sexe m'intéresse moins qu'avant.
2 Le sexe m'intéresse beaucoup moins maintenant.
3 J'ai perdu tout intérêt pour le sexe.
Tous droits réservés © 1997 par Aaron T. Beck.  
